Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is -14.29% lower on its value in year-to-date trading and has touched a low of $6.07 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHAT stock was last observed hovering at around $7.13 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $6.96, the stock is -7.45% and -25.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.87 million and changing -2.38% at the moment leaves the stock -41.92% off its SMA200. PHAT registered -7.32% loss for a year compared to 6-month loss of -42.53%. The firm has a 50-day simple moving average (SMA 50) of $9.5788 and a 200-day simple moving average (SMA200) of $12.001225.
The stock witnessed a -11.79% gain in the last 1 month and extending the period to 3 months gives it a -55.56%, and is 0.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.03% over the week and 7.26% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $475.91M and $26.27M in sales. Profit margin for the company is -1292.14%. Distance from 52-week low is 14.76% and -64.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-109.14%).
with sales reaching $26.04M over the same period.The EPS is expected to shrink by -37.62% this year, but quarterly earnings will post 7,471.03% year-over-year. Quarterly sales are estimated to grow 3,718.56% in year-over-year returns.
197.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 118.30% of the company’s shares. The shares outstanding are 68.32M, and float is at 34.87M with Short Float at 42.89%. Institutions hold 109.16% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.3189 of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.788 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9906 and valued at over $35.84 million, while INVESCO LTD. holds 5.3853 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider sale by Nabulsi Azmi, the company’s Chief Operating Officer. SEC filings show that Nabulsi Azmi sold 1,118 shares of the company’s common stock on Dec 19 ’24 at a price of $8.00 per share for a total of $8944.0. Following the sale, the insider now owns 0.24 million shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 19 ’24 that Henderson Molly (CFO and CBO) sold a total of 1,291 shares of the company’s common stock. The trade occurred on Dec 19 ’24 and was made at $8.00 per share for $10328.0. Following the transaction, the insider now directly holds 98156.0 shares of the PHAT stock.
Still, SEC filings show that on Dec 13 ’24, KARBE FRANK (Director) acquired 12,500 shares at an average price of $7.93 for $99084.0. The insider now directly holds 57,000 shares of Phathom Pharmaceuticals Inc (PHAT).
